

JOSH STEIN • Governor

DEVDUTTA SANGVAI • Secretary

DEBRA FARRINGTON • Deputy Secretary for Health

MICHAEL LEIGHS • Deputy Secretary for Opportunity & Well-Being

KELLY KIMPLE • Director, Division of Public Health

YVONNE COPELAND • Director, Division of Child and Family Well-Being

Memo

To: North Carolina Newborn Screening System Partners

From: Scott M. Shone, PhD, HCLD(ABB), Director, NC State Laboratory of Public Health

Anne O. Odusanya, DrPH, MPH, Assistant Director, Division of Child and Family Well-

Being, Whole Child Health Section

Date: August 26, 2025

Re: Newborn Screening for Mucopolysaccharidosis Type II

Beginning August 30, 2025, the North Carolina Newborn Screening Program will begin screening all newborn screening specimens submitted to the North Carolina State Laboratory of Public Health (NCSLPH) for Mucopolysaccharidosis Type II (MPS II). MPS II is a lysosomal storage disease (LSD), a type of genetic disease that is characterized by an abnormal build-up of various toxic materials in the body's cells. Symptoms and onset of LSDs vary and may affect different parts of the body, including the skeleton, brain, skin, heart, and central nervous system.

Newborn screening for MPS II will be integrated into the standard newborn screening panel and results will be included on all NCSLPH Newborn screening reports. Reports are provided in hard copy form and are also available via the NCSLPH Clinical and Environmental Lab Results (CELR) online portal.

Screening results that suggest elevated risk for MPS II will be communicated to the newborn's health care provider by the UNC Division of Genetics and Metabolism. The UNC Program will provide consultation services and recommendations for follow-up testing.

For questions about the newborn screening laboratory testing for MPS II, please contact the NCSLPH Newborn Screening Laboratory at 919-733-3937.

NC DEPARTMENT OF HEALTH AND HUMAN SERVICES • DIVISION OF PUBLIC HEALTH • STATE LABORATORY OF PUBLIC HEALTH